David Sheppard
Direttore/Membro del Consiglio presso Locki Therapeutics Ltd.
Provenienza dei contatti di primo grado di David Sheppard
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Locki Therapeutics Ltd.
Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases.
7
| Holding Company | Biotechnology | 7 |
Revona Bio Ltd.
Revona Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Revona Bio Ltd. is a British biotechnology company that specializes in the development of RNA targeted drugs. The company was founded in 2022 by Anastasia Jane Callaghan and Charlotte Anne Henderson.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a David Sheppard tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
VERNALIS | Pharmaceuticals: Major | Director/Board Member | |
GENEDRIVE PLC | Medical Specialties | Chairman | |
Stanford University | College/University | Doctorate Degree | |
University of Pennsylvania | College/University | Undergraduate Degree | |
University of Bath | College/University | Doctorate Degree | |
AXIS-SHIELD LTD | Medical Specialties | Chief Executive Officer | |
University of Oxford | College/University | Graduate Degree | |
University of Bristol | College/University | Undergraduate Degree | |
Victoria University of Wellington | College/University | Undergraduate Degree | |
Lifearc
Lifearc Miscellaneous Commercial ServicesCommercial Services Lifearc provides research services. It specializes in intellectual property management, drug discovery, medical diagnostics and antibody engineering. The firm services include complete technology transfer service for scientists in MRC units and institutes, Awards to Inventors, Collaborative drug discovery and antibody engineering, Funding early stage research with commercial/translational potential and protecting new ideas. The company is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Chairman | |
Cytox Ltd.
Cytox Ltd. Medical DistributorsDistribution Services Cytox Ltd. develops products and services for neurodegenerative disorders. It develops cellular and genetic assays for Alzheimer’s disease diagnosis. The firm offers biomarker services to pharmaceutical companies conducting clinical trials with drugs for the treatment of AD and mild cognitive impairment; and drug-screening services. The company was founded by Zsuzsanna Nagy, Margaret Esiri, Roy Bicknell and James S. Chadwick in 2004 and is headquartered in Oxford, the United Kingdom. | Medical Distributors | Chairman | |
venBio Partners LLC
venBio Partners LLC Investment ManagersFinance venBio Partners LLC (venBio) is a venture capital subsidiary of Venbio Partners LP founded in 2009 by Adelman robert and Goodman corey. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor | |
Yissum Holdings Ltd. | Corporate Officer/Principal | ||
Integra Holdings Ltd.
Integra Holdings Ltd. MiscellaneousMiscellaneous Integra Holdings Ltd. operates as a holding company. It invests in the pharmaceutical industry. The company was founded in 2012 and is headquartered in Jerusalem, Israel. | Miscellaneous | Corporate Officer/Principal | |
Stowheath Ltd.
Stowheath Ltd. Miscellaneous Commercial ServicesCommercial Services Stowheath Ltd. is a British company that provides professional, scientific, and technical services. The private company is based in London, UK. The company was founded in 2011. | Miscellaneous Commercial Services | Director/Board Member | |
Enso Ventures Ltd.
Enso Ventures Ltd. Investment ManagersFinance Enso Ventures Ltd (Enso Ventures) is an independent venture capital firm founded in 2010 by Nikolay Danilov. The firm is headquartered in London, United Kingdom. | Investment Managers | Director of Finance/CFO | |
The Hebrew University Hadassah Medical School | College/University | Doctorate Degree | |
HORIZON DISCOVERY GROUP PLC | Medical Specialties | Chairman | |
Concepta Diagnostics Ltd.
Concepta Diagnostics Ltd. Medical SpecialtiesHealth Technology Concepta Diagnostics Ltd. engages in the development of products for the female health diagnostics sector. The company was founded by Steven Koon Ching Lee and Robert Andrew Porter on January 15, 2013 and is headquartered in Cardiff, the United Kingdom. | Medical Specialties | Director/Board Member | |
Delta Diagnostics (UK) Ltd.
Delta Diagnostics (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Delta Diagnostics Ltd. develops and provides assays diagnostics solutions. It offers cystic fibrosis, rapid aneuploidy analysis, and genetic disease diagnosis. The company was founded in 1994 and is headquartered in Lancashire, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
PLIANT THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal | |
PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member | |
Snoody Ltd.
Snoody Ltd. Medical SpecialtiesHealth Technology Snoody Ltd. develops and supplies antiviral and healing technology for various product applications. It provides wound dressings, mastitis prevention products, ulcer preventing socks, face masks, and integrated pathogen defense products. The company was founded in 2009 by Paul Francis Hope and is headquartered in Manchester, the United Kingdom. | Medical Specialties | Founder | |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
Arrakis Therapeutics, Inc.
Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member | |
Arkin Bio Ventures
Arkin Bio Ventures Investment ManagersFinance Arkin Bio Ventures (Arkin Bio) is a venture capital arm of Arkin Holdings founded in 2016. The firm is headquartered in Tel Aviv, Israel. | Investment Managers | Private Equity Investor | |
Aeovian Pharmaceuticals, Inc.
Aeovian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA. | Pharmaceuticals: Major | Director/Board Member | |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member | |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Comptroller/Controller/Auditor | |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
Auron Therapeutics, Inc.
Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Miscellaneous Commercial Services | Director/Board Member | |
APTAMER GROUP PLC | Biotechnology | Chairman | |
WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Arkin Holdings
Arkin Holdings Real Estate Investment TrustsFinance Arkin Holdings engages in the provision of healthcare investment services which specializes in pharmaceutical and biotechnology, medical devices, dermatology, and hedge fund. The company was founded by Mori Arkin in 2009 and is headquartered in Herzliya, Israel. | Real Estate Investment Trusts | Corporate Officer/Principal | |
VENTYX BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
ELEVATION ONCOLOGY, INC. | Biotechnology | Director/Board Member | |
Mote Research Ltd.
Mote Research Ltd. Miscellaneous Commercial ServicesCommercial Services Mote Research Ltd. engages in research and experimental development on natural sciences and engineering. The private company is based in Cambridge, UK and was founded in 2015. | Miscellaneous Commercial Services | Director/Board Member | |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member | |
Pharvaris GmbH
Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | Miscellaneous Commercial Services | Director/Board Member | |
Photys Therapeutics, Inc.
Photys Therapeutics, Inc. Medical SpecialtiesHealth Technology Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation. | Medical Specialties | Director/Board Member | |
35Pharma, Inc.
35Pharma, Inc. Pharmaceuticals: MajorHealth Technology 35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov. | Pharmaceuticals: Major | Director/Board Member | |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a private company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. The company is focused on developing a gene replacement approach to treat autosomal dominant Alzheimer's disease (ADAD). Specifically, they are working on a gene therapy that targets mutations in the presenilin 1 gene (PSEN1), which is the underlying genetic cause of ADAD. | Biotechnology | Director/Board Member | |
Entact Bio, Inc.
Entact Bio, Inc. BiotechnologyHealth Technology Entact Bio, Inc. is a company that focuses on creating new medicines by enhancing protein function. The company is based in Watertown, MA. The company is a team of scientists, entrepreneurs, drug creators, and problem solvers who work together to bring new medicines to patients who currently have few options. The CEO of the company is Victoria M. Richon. The founder of the company grew up in chaos and instability in an undisclosed capital city and has always been passionate and motivated to help enhance and provide medical solutions. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Octiocor Ltd.
Octiocor Ltd. BiotechnologyHealth Technology Octiocor Ltd. is a British biotechnology company founded in 2022. The company is based in Cambridge, UK and engages in research and development of biotechnology. | Biotechnology | Director/Board Member | |
Ephyra Ltd.
Ephyra Ltd. BiotechnologyHealth Technology Ephyra Ltd. is a British biotechnology company founded in 2022 that engages in research and development. The company is based in Cambridge, UK. | Biotechnology | Director/Board Member | |
Tagomics Ltd.
Tagomics Ltd. Miscellaneous Commercial ServicesCommercial Services Tagomics Ltd. is a British company founded in 2020 that works to transform disease diagnosis through comprehensive epigenomic profiling. The company is based in Birmingham, UK. The company's website is currently being finalized and will be online soon. The website uses cookies to improve user experience and analyze website usage. | Miscellaneous Commercial Services | Director/Board Member | |
Horizon Discovery Ltd.
Horizon Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Horizon Discovery Ltd. develops and supplying patient-relevant drug discovery and diagnostic research tools. The frm also supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. The company was founded by Christopher John Torrance and Alberto Bardelli on February 14, 2005 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Chairman | |
Disruptive Capital Finance LLP
Disruptive Capital Finance LLP Investment ManagersFinance Disruptive Capital Finance LLP (Disruptive Capital) is a private equity firm founded in 2006 by Cédriane Marie de Boucaud Truell, Edmund George Truell and Roger Le Tissiermr. The firm is headquartered in London. | Investment Managers | Director of Finance/CFO |
Statistiche
Distribuzione geografica
Regno Unito | 23 |
Stati Uniti | 17 |
Israele | 7 |
Paesi Bassi | 3 |
Nuova-Zelanda | 2 |
Settori
Health Technology | 26 |
Commercial Services | 10 |
Consumer Services | 8 |
Finance | 7 |
Distribution Services | 2 |
Posizioni
Director/Board Member | 54 |
Corporate Officer/Principal | 10 |
Chairman | 8 |
Independent Dir/Board Member | 8 |
Undergraduate Degree | 6 |
Contatti più connessi
Insiders | |
---|---|
Ian Gilham | 20 |
Alon Lazarus | 18 |
Richard Gaster | 17 |
Andrew Sinclair | 14 |
Owen Smith | 6 |
Jason Mellad | 6 |
Edward McGill | 5 |
Owen Philip Smith | 1 |
Colin Walsh | 1 |
Anastasia Callaghan | 1 |
Charlotte Henderson | 1 |
Jeremy Howells | 1 |
- Borsa valori
- Insiders
- David Sheppard
- Connessioni Società